It has also been shown that NF-κB receptor activator (RANKL) is a potent stimulator of NF-κB and that systemic or hepatic blockade of RANKL signaling leads to significant improvements in hepatic insulin sensitivity and prevents the development of diabetes (158). The gene discussed is INS; the disease is diabetes mellitus.